Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Veronica HuberLorenza Di GuardoLuca LalliDaniele GiardielloAgata CovaPaola SquarcinaPaola FratiAnna Maria Di GiacomoLorenzo PillaMarcella TazzariChiara CamisaschiFlavio ArientiChiara CastelliMonica RodolfoValeria BerettaMassimo Di NicolaMichele MaioMichele Del VecchioFilippo de BraudLuigi MarianiLicia RivoltiniPublished in: Journal for immunotherapy of cancer (2021)
The MIS >0 identifies melanoma patients with a more aggressive disease, thus acting as a simple blood biomarker that can help tailoring therapeutic choices in real-life oncology.